Millions of people in the United States have a circulatory problem of the legs called peripheral vascular disease. It can be painful and may even require surgery in serious cases. This disease can lead to severe skeletal muscle wasting and, in turn, limb amputation.
At The University of Texas Health Science Center at Houston (UTHealth) Medical School, scientists tested a non-surgical preventative treatment in a mouse model of the disease and it was associated with increased blood circulation. Their proof-of-concept study appears in the journal Cell Reports.
Working to develop a new treatment for peripheral vascular disease from left to right are UTHealth researchers Vikas Yadav, Ph.D., Sabina Lorca and Vihang Narkar, Ph.D.
Credit: The University of Texas Health Science Center at Houston (UTHealth)
Unlike previous studies in which other investigators used individual stimulatory factors to grow blood vessels, Vihang Narkar, Ph.D., senior author and assistant professor in the Department of Integrative Biology and Pharmacology at the UTHealth Medical School, identified and turned off a genetic switch that stifles blood vessel development.
"We discovered an inhibitory switch that degrades blood vessels," said Narkar, whose laboratory is in the UTHealth Center for Metabolic and Degenerative Diseases at The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases. "We were able to genetically turn it off to prevent peripheral vascular disease in a preclinical study."
Added Narkar, "Our next step will be to test this targeted treatment in models of other conditions that dramatically decrease circulation like diabetes and atherosclerosis."
Narkar said using individual growth factors to stimulate blood vessel growth often leads to the formation of leaky and non-functional blood vessels. "By turning off a genetic switch that acts as a roadblock for blood vessel growth, we were able to trigger and accelerate the natural process of blood vessel regeneration that involves a battery of growth factors," he said.
The switch is called peroxisome proliferator-activated receptor gamma co-activator 1 beta (PGC1beta) and could be a key to future treatments for additional conditions like cardiac myopathies, cancer and retinopathy.
Narkar's UTHealth co-authors are Vikas Yadav, Ph.D. (lead author), Antonios Matsakas, Ph.D., and Sabina Lorca. Narkar is on the faculty of The University of Texas Graduate School of Biomedical Sciences at Houston.
The study titled "PGC1beta activates anti-angiogenic program to repress neo-angiogenesis in muscle ischemia" received support from the American Heart Association (AHA#11SDG7600213), American Diabetes Association (ADA#1-13-BS-127) and Muscular Dystrophy Association (MDA#174408).
Robert Cahill | Eurek Alert!
Breaking through a double wall with a sledgehammer
29.06.2015 | Max-Planck-Institut für Entwicklungsbiologie
Lean but sated: Molecular Switch for a Healthy Metabolism discovered
29.06.2015 | Leibniz-Institut für Altersforschung - Fritz-Lipmann-Institut e.V. (FLI)
Think of an object made of iron: An I-beam, a car frame, a nail. Now imagine that half of the iron in that object owes its existence to bacteria living two and a half billion years ago.
Think of an object made of iron: An I-beam, a car frame, a nail. Now imagine that half of the iron in that object owes its existence to bacteria living two and...
A team of scientists including PhD student Friedrich Schuler from the Laboratory of MEMS Applications at the Department of Microsystems Engineering (IMTEK) of...
The three-year clinical trial results of the retinal implant popularly known as the "bionic eye," have proven the long-term efficacy, safety and reliability of...
On June 23, the second Sentinel mission was launched from the space mission launch center in Kourou. A critical component of Aachen is on board. Researchers at the Fraunhofer Institute for Laser Technology ILT and Tesat-Spacecom have jointly developed the know-how for space-qualified laser components. For the Sentinel mission the diode laser pump module of the Laser Communication Terminal LCT was planned and constructed in Aachen in cooperation with the manufacturer of the LCT, Tesat-Spacecom, and the Ferdinand Braun Institute.
After eight years of preparation, in the early morning of June 23 the time had come: in Kourou in French Guiana, the European Space Agency launched the...
(Nano)islands that slide freely on a sea of copper, but when they become too large (and too dense) they end up getting stuck: that nicely sums up the system...
25.06.2015 | Event News
16.06.2015 | Event News
11.06.2015 | Event News
29.06.2015 | Life Sciences
29.06.2015 | Life Sciences
29.06.2015 | Physics and Astronomy